CD81 通过阻断 CD274/PD-L1 的选择性自噬降解驱动放射抵抗性胶质母细胞瘤的免疫逃逸
CD81 drives immune evasion in radioresistant glioblastoma by blocking selective autophagic degradation of CD274/PD-L1.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
胶质母细胞瘤患者接种 DCVax-L 疫苗：真正的希望还是阴性试验？辩论仍在继续
英文原题：DCVax-L Vaccination in Patients with Glioblastoma: Real Promise or Negative Trial? The Debate Is Open.
查看英文原题
DCVax-L Vaccination in Patients with Glioblastoma: Real Promise or Negative Trial? The Debate Is Open.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
过去几十年间，GB患者的预后缺乏显著改善，这凸显出需要创新疗法来对抗这一恶性肿瘤并提高生存结局。DCVax-L（负载自体肿瘤裂解物的树突状细胞疫苗）的III期临床试验结果已表明，其可延长新诊断和复发胶质母细胞瘤的中位生存期和长期生存期，因此受到科学界的热烈欢迎。然而，这项研究在方法学问题上值得反思，涉及主要终点变更、入组周期过长，以及用作对照臂的外部对照人群有效性欠佳。
展开英文摘要原文
The lack of significant improvement in the prognosis of patients with GB over the last decades highlights the need for innovative treatments aimed at fighting this malignancy and increasing survival outcomes. The results of the phase III clinical trial of DCVax-L (autologous tumor lysate-loaded dendritic cell vaccination), which has been shown to increase both median survival and long-term survival in newly diagnosed and relapsed glioblastoma, have been enthusiastically received by the scientific community.
However, this study deserves some reflections regarding methodological issues related to the primary endpoint change, the long accrual period, and the suboptimal validity of the external control population used as the comparison arm.
论文信息
- 作者
- Gatto L、Di Nunno V、Tosoni A、Bartolini S、Ranieri L、Franceschi E
- 第一作者单位
- Department of Oncology, Azienda Unità Sanitaria Locale (AUSL) Bologna, 40139 Bologna, Italy.Italy
- 通讯作者单位
- Nervous System Medical Oncology Department, IRCCS Istituto delle Scienze Neurologiche di Bologna, 40139 Bologna, Italy.Italy
- 期刊
- Cancers2023 Jun 20
- 原文标识
- PubMed 37370860 · DOI 10.3390/cancers15123251
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →